# US 2024/0197768 A1 · Methods and compositions for disrupting biofilm utilizing chitosan-derivative compounds

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0197768 A1
- Document ID: US20240197768A1
- Status: Published application
- Kind: A1
- Application number: 18/238,836
- Filed: 2023-08-28
- Published: 2024-06-20
- Earliest claimed: 2009-09-02
- Assignees: Synedgen, Inc.
- Applicants: Synedgen, Inc.
- Inventors: Shenda M. Baker; William P. Wiesmann; Stacy Marie Townsend
- Web page: https://patentgrep.com/patent/US20240197768A1

## CPC

- A61K 31/722: Chitin, chitosan
- A61K 9/0014: {Skin, i.e. galenical aspects of topical compositions (non-active ingredients are additionally classified in A61K47/00; A61K9/0009, A61K9/0021, A61K9/7015, A61K9/7023 take precedence; cosmetic preparations A61K8/00, A61Q; preparations for wound dressings or bandages A61L26/00)}
- A61K 9/0043: {Nose}
- A61K 9/0053: {Mouth and digestive tract, i.e. intraoral and peroral administration}
- A61P 11/00: Drugs for disorders of the respiratory system
- A61P 11/12: Mucolytics
- A61P 17/00: Drugs for dermatological disorders
- A61P 31/04: Antibacterial agents
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

Described herein are methods of disrupting (e.g., reducing the viscosity of, or dissolving) a preformed biofilm in a subject, the method comprising: administering to the subject an effective amount of a composition comprising a soluble chitosan or derivatized chitosan wherein the soluble chitosan or derivatized chitosan when administered contacts the preformed biofilm, thereby disrupting (e.g., reducing the viscosity of, or dissolving) the preformed biofilm.

## Claims

### Claim 1

A method of disrupting a preformed biofilm in a subject infected with bacteria selected from the group consisting of Burkholderia cepacia genomovar cenocepacia, Burkholderia cepacia genomovar dolosa, Burkholderia cepacia complex, Staphylococcus aureus, Pseudomonas aeruginosa, Acinetobacter baumanii, Streptococcus pneumoniae, and Klebsiella pneumoniae, the method comprising:
administering to the subject by inhalation a therapeutically effective amount of a composition comprising a derivatized chitosan wherein the derivatized chitosan comprises a chitosan of the following formula (I):
wherein:
n is an integer between 20 and 6000; and
each R1 is independently selected for each occurrence from hydrogen, acetyl, and a group of formula (II): wherein formula (II) is selected from
wherein at least 25% of R1 substituents are H, at least 100 of R1 substituents are acetyl, and at least 4-30% of R1 substituents are a group of formula (II) the molecular weight of the derivatized chitosan is between 10,000 and 150,000 Da, and the polydispersity index (PDI) of the derivatized chitosan is between 1.5 and 2.5, wherein, upon administration, the composition disrupts the preformed biofilm in the respiratory system of the subject and reduces the viscosity of sputum in the respiratory system of the subject relative to the sputum prior to administration of the composition.

### Claim 2 (depends on 1)

The method of claim 1, wherein the PDI of the derivatized chitosan is between 1.5 and 2.3.

### Claim 3 (depends on 1)

The method of claim 1, wherein the PDI of the derivatized chitosan is between 1.5 and 2.0.

### Claim 4 (depends on 1)

The method of claim 1, wherein the method reduces the viscosity of the sputum by at least 50% compared to the sputum that has not been contacted with the composition.

### Claim 5 (depends on 1)

The method of claim 1, wherein the method reduces the viscosity of the sputum by at least 80% compared to the sputum that has not been contacted with the composition

### Claim 6 (depends on 1)

The method of claim 1, wherein the method increases the pourability of sputum compared to the sputum that has not been contacted with the composition.

### Claim 7 (depends on 1)

The method of claim 1, wherein the derivatized chitosan is present in the composition at a concentration of about 10 to 250 μg/mL.

### Claim 8 (depends on 1)

The method of claim 1, wherein the biofilm is partially dissolved compared to the biofilm that has not been contacted with the composition.

### Claim 9 (depends on 1)

The method of claim 1, wherein the biofilm is in the respiratory system.

### Claim 10 (depends on 1)

The method of claim 1, wherein the subject has cystic fibrosis.

### Claim 11 (depends on 1)

The method of claim 1, wherein the derivatized chitosan is soluble in aqueous solution from about pH 6.8 to about pH 7.4.

### Claim 12 (depends on 1)

The method of claim 1, wherein the molecular weight of the derivatized chitosan is between 10,000 and 150,000 Da.

### Claim 13 (depends on 1)

The method of claim 1, wherein the chitosan is functionalized at between 20% and 30%.

### Claim 14 (depends on 1)

The method of claim 1, wherein the degree of deacetylation (% DDA) of the derivatized chitosan is between 75% and 95%.

### Claim 15 (depends on 1)

The method of claim 1, wherein the therapeutically effective amount is from about 5 to 500 μg/mL.

### Claim 16 (depends on 1)

The method of claim 1, further comprising administering an antibiotic, anti-inflammatory, or mucolytic compound to the subject in conjunction with, prior to, or subsequent to the administration of the composition.

### Claim 17 (depends on 1)

The method of claim 1, wherein the bacteria are multidrug resistant.

### Claim 18 (depends on 1)

The method of claim 1, wherein between 25-95% of R1 substituents are hydrogen.

### Claim 19 (depends on 1)

The method of claim 1, wherein between 1-50% of R1 substituents are acetyl.

### Claim 20 (depends on 1)

The method of claim 1, wherein 55-90% of R1 substituents are hydrogen, 4-20% of R1 substituents are acetyl, and 4-30% of R1 substituents are a group of formula (II).
